Hims to stop offering GLP-1 pill after FDA warned of crackdown

Hims & Heres Health Inc. announced on Monday its decision to immediately stop offering its compounded GLP-1 weight-loss pills following a stern regulatory warning from the U.S. Food and Drug Administration (FDA) regarding the safety and legality of unapproved versions of these medications. The telehealth company, based in San Francisco, moved to suspend the oral versions of the popular appetite suppressants to ensure compliance with federal standards as the agency begins a nationwide crackdown on pharmacies and distributors selling non-patented alternatives to brand-name drugs like Wegovy and Ozempic. This strategic pivot comes as the pharmaceutical industry faces immense pressure to resolve supply shortages while maintaining strict oversight of drug manufacturing processes. The FDA’s intervention stems from growing concerns over the proliferation of compounded GLP-1 medications, which are often produced by pharmacies when a drug is on the official shortage list. However, federal regulators warned that some companies were stretching these legal exemptions to market oral formulations that have not undergone the same rigorous clinical testing as the original injectable versions developed by Novo Nordisk. By preemptively removing the pill from its platform, Hims & Hers aims to avoid potential litigation and regulatory sanctions that could jeopardize its broader telehealth operations and its recently launched injectable GLP-1 program. While the oral pill is being shelved, Hims & Hers continues to offer compounded injectable semaglutide, capitalizing on the high demand for weight-loss treatments. The company’s stock experienced significant volatility following the announcement, reflecting investor concerns over how the regulatory shift will impact the firm's long-term revenue targets. Industry analysts suggest that this move highlights the delicate balance telehealth providers must strike between providing affordable access to in-demand therapies and navigating the complex legal boundaries established by the FDA and big pharmaceutical manufacturers. The situation remains fluid as the FDA clarifies which specific formulations remain permissible under current shortage protocols.